放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤

Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.     

血栓通治疗老年早期糖尿病肾病疗效观察

对老年早期糖尿病肾病患者,采用血栓通治疗,并与对照组比较.结果治疗组与对照组比较,血液流变学各项参数水平指标、尿白蛋白排泄率及肾功能指标均有显著性差异(P＜0.05).结论血栓通是治疗老年早期糖尿病肾病较好药物.     

益心汤治疗慢性心力衰竭临床观察

心力衰竭(chronic heart failure,CHF)是心脏病的终末阶段,死亡率及致残率均较高,是严重危害人类健康的疾病,单纯西药治疗复发率高。2001-08—2004-10,笔者在常规治疗基础上加用益心汤治疗慢性心力衰竭30例,并与常规治疗30例对照观察,现报告如下。1资料与方法1.1一般资料全部60     

慢性咳嗽的治疗

慢性咳嗽病因复杂，明确病因是治疗成功的关键。多数慢性咳嗽与感染无关，无需使用抗菌药物。咳嗽原因不明或不能除外感染时，慎用糖皮质激素。     

星级服务措施的实施体会

质量就是效益，质量就是生命。护理服务质量的好坏直接关系到一个医院的生存与发展。为把提高护理服务质量落到实处，真正实现“以病人为中心，满足病人需要为目标”的护理服务宗旨，我科自2003年2月起，开展星级服务活动，以增强护士服务意识．优化服务环境，有力的提高了护理服务质量，取得了良好的社会效益，让病人在科室感到温馨如家。     

1例卵巢幼年型颗粒细胞瘤患儿的护理

卵巢幼年型颗粒细胞瘤(JGCT)是一种罕见的性索间质肿瘤,占卵巢颗粒细胞瘤的5%[1-2],2007年1月我科收治1例卵巢幼年型颗粒细胞瘤的患儿,接受手术 化学药物治疗,预后良好。现将护理体会介绍如下。1病例介绍患儿,女性,1岁6个月,因白带增多,阴道持续点滴出血2周,诊断为左卵巢幼年型     

空降兵某部口腔健康教育一年后牙周指数的变化

我们在2001年对空降兵某部人群口腔牙周健康情况进行流行病学调查，同时，针对性地实施口腔健康教育，一年后，再次进行流行病学调查，并对两次调查情况进行比较，报告如下。     

拔牙术诱发周期性低血钾致心脏停搏抢救成功1例

1病例报告 患者女，24岁。因左下第三磨牙水平阻生在我院口腔科门诊行劈冠拔除术。术前否认心血管等慢性疾病史，无药物过敏史。拔牙术进行约20min时，患者突然烦躁不安、四肢抽动、呼吸困难、口唇发绀，随即意识丧失，颈动脉博动消失，听诊心音消失，血压为零。手术医师立即清除口内血液行口对口人工呼吸、胸外心脏按压术，并皮下注射肾上腺素1mg。急诊科医师迅速协助进行心肺复苏术，     

慢性充血性心力衰竭患者的家庭护理和康复指导体会

慢性充血性心力衰竭(CHF)是各种心血管疾病的严重阶段,其住院率和死亡率都较高。在我国,引起慢性充血性心力衰竭的基础心脏病以冠状动脉疾病和高血压病为主。CHF患者经过住院治疗,病情稳定后,大多选择回到家中继续治疗。笔者自2005年3月~11月对26例住院的CHF患者通过出院时指导、电话联系、登门随访等形式,对病人及家庭进行相关家庭护理和康复的指导与培训。经采用正确的护理和康复方法,一定程度地提高了患者的生活质量,减少了再次住院率,取得了满意的效果。现将其护理体会介绍如下。1家庭护理方法指导1.1心理护理慢性充血性心力衰竭患…     

正常人群非特异性细胞免疫功能实验研究

目的：了解正常人群的细胞免疫功能状态，为制定正常值范围提供依据。方法：采集正常人血液，加入含植物血凝素（pHa）的细胞培养基中培养一定时间后，观察母细胞化的淋巴细胞百分率。结果：2～7岁组PHA刺激的淋巴细胞转化率（以下简称淋转率）为85．91％，自发淋转率为8．69％；8～15岁组的淋转率为84．46％，自发淋转率为8．21％；16～55岁组的淋转率为83．25％，自发淋转率为9．45％；大于55岁组的淋转率为77，75％，自发淋转率为8．63％。结论：各年龄组的人均有自发的淋巴细胞母细胞化现象，其转化率没有显著性差异；PHA淋转率则有显著性差异。